Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing

Diana Mandelker, Paola Cin, Heather A. Jacene, Philippe Armand, Richard M. Stone, Neal I. Lindeman

Research output: Contribution to journalArticlepeer-review

Abstract

Next generation sequencing (NGS) is increasingly being used clinically to characterize the molecular alterations found in patients' tumors. These testing results have the potential to affect clinical care by guiding therapeutic approaches based upon genotype. NGS based testing approaches have a distinct advantage over provider-ordered single gene testing in that they can detect unexpected, yet clinically important genetic changes. Here, we illustrate this principle with the case of a 33-year-old man with myeloid sarcoma that was refractory to six different chemotherapeutic regimens. Our clinical NGS assay detected an unanticipated FIP1L1-PDGFRA rearrangement in his tumor. The patient was immediately placed on Imatinib therapy to which he responded, and remains in remission 10 months after the rearrangement was initially detected.

Original languageEnglish (US)
Article number30
JournalExperimental Hematology and Oncology
Volume4
Issue number1
DOIs
StatePublished - Oct 8 2015

Keywords

  • FIP1L1-PDGFRA
  • Myeloid sarcoma
  • Next generation sequencing
  • Somatic sequencing

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing'. Together they form a unique fingerprint.

Cite this